Developer docs
API playgroundTry for free, no card

Search company profiles

Ciloa

Full company profile

uuid0000xxg

Namestring
Ciloa
Legal namestring
Ciloa SAS
Websiteurl
ciloa.fr
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Ciloa SAS is a French privately-held biotechnology company founded in 2011 and headquartered in Montpellier, France, specializing in the bioengineering of small extracellular vesicles (sEVs/exosomes) for therapeutic and preventive applications. The company's core technology is the proprietary EVENGI platform, developed over 20 years of extracellular vesicle research, which has generated over 100 different bioengineered sEVs containing proteins of medical interest. Its lead product candidate is APN-sEV — sEVs loaded with stable, highly multimerised, functional adiponectin hormone — targeted at metabolic diseases including obesity, type 2 diabetes, MAFLD/MASH, and cardiovascular disease, with clinical trials (Phase I in 2027, Phase IIa in 2028) planned for the APN-sEV candidate.

Ciloa's business model is a pre-revenue biopharmaceutical development model: the company is not yet commercializing any products and will generate revenue through future drug commercialization or licensing once its therapeutic candidates complete clinical trials and receive regulatory approval. The platform also supports applications in oncology, rare diseases, age-related illnesses, and viral pandemic preparedness through sEV-based vaccines. To date, the company has been funded primarily through non-dilutive government grants, securing €5 million in March 2022 from the France 2030 initiative for biomedicines and vaccines development, and €6.5 million in July 2025 under the 'DIADEME' project for scaling up manufacturing and advancing APN-sEV through preclinical and clinical trials, bringing cumulative disclosed funding to approximately €11.5 million.

The company operates with a small team (1-10 employees) and pursues an enterprise-oriented go-to-market, engaging potential pharmaceutical partners and investors through industry conferences such as BIO US 2025 (as part of the French Delegation) and the EU-Japan Biotech & Pharma Conference. Ciloa has also entered a strategic co-development partnership with Bio-Sourcing and Intract Pharma under the AB-BIOBETTER EU project (€3.4 million total, €1.9 million in Eureka Eurostars subsidies) to develop an oral formulation of adalimumab for inflammatory indications, demonstrating a willingness to expand the platform beyond metabolic disease applications.

Short descriptiontext

Ciloa is a French pre-revenue biotech developing bioengineered small extracellular vesicles (sEVs) via its proprietary EVENGI platform, with a lead APN-sEV candidate targeting obesity and type 2 diabetes through planned Phase I trials in 2027.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMontpellier, France
HQ citystring
Montpellier
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
extracellular vesicles therapeutics, biopharmaceutical drug development, metabolic disease treatments, exosome bioengineering, adiponectin therapeutics
Industry2 codes
PRIMARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Dog and Cat Food Manufacturing311111
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Therapeutic Drug Development
TypeOne Time License
Description

Pre-revenue biopharmaceutical company developing drug candidates (APN-sEV) for obesity and type 2 diabetes. Revenue will be generated through eventual drug commercialization pending successful clinical trials and regulatory approvals.

ciloa.bio
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Ciloa develops bioengineered small extracellular vesicles (sEVs/exosomes) as therapeutic drug candidates using its proprietary EVENGI platform. Its lead candidate, APN-sEV, consists of sEVs loaded with stable, highly multimerised functional adiponectin hormone and targets metabolic diseases—specifically obesity, type 2 diabetes, MAFLD/MASH, and cardiovascular disease—by restoring insulin sensitivity, reducing lipogenesis, and preserving lean muscle mass. The pipeline also extends to oncology, rare diseases, age-related illnesses, and vaccine development against viral pandemics.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Spectacular effects on obesity and diabetes characterized by decreased circulating adiponectin
Product overview1 text field

Ciloa is a biotech company pioneering the bioengineering of small extracellular vesicles (sEVs/exosomes) as natural therapeutic messengers. The company's core offering centers on its proprietary EVENGI Platform, which generates bioengineered sEVs containing proteins of medical interest. The lead product is APN-sEVs—sEVs containing functional adiponectin hormone—for treating metabolic diseases including obesity, type 2 diabetes, MAFLD/MASH, and cardiovascular diseases. Ciloa's technology enables stable, ready-to-use, affordable medicines that can be stored in refrigerators for years.

Product and service1 record
1APN-sEVs
CategoryBiopharmaceutical therapeutic candidate
Description

Bioengineered small extracellular vesicles (sEVs) containing stable, highly multimerised and functional adiponectin hormone, developed as therapeutic drug candidates for metabolic diseases including obesity and type 2 diabetes. APN-sEVs provide insulin-sensitizing, anti-inflammatory, and anti-oxidative stress properties while protecting lean muscle mass during treatment.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-28
Description

Ciloa partnered with Bio-Sourcing and Intract Pharma on the AB-BIOBETTER project, a €3.4 million EU project funded with €1.9M subsidies from Eureka Eurostars. The project aims to pioneer development of new oral formulation of adalimumab for inflammatory indications.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-28
Description

Ciloa partnered with Bio-Sourcing and Intract Pharma on the AB-BIOBETTER project, a €3.4 million EU project funded with €1.9M subsidies from Eureka Eurostars. The project aims to pioneer development of new oral formulation of adalimumab for inflammatory indications.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UK-based biotech engineering exosomes/extracellular vesicles for therapeutic delivery of proteins, RNA, and other payloads across rare diseases and CNS indications. Most directly comparable to Ciloa's EVENGI platform given shared core modality of bioengineered sEVs for therapeutic use.

TypeDirect peer
Description

Clinical-stage biotech developing extracellular vesicle-based therapeutics, including lead program CAP-1002 for Duchenne muscular dystrophy and inflammatory conditions. Comparable to Ciloa as an EV-therapeutics pure-play advancing assets toward clinical milestones.

TypeDirect peer
Description

US biotech developing engineered extracellular vesicles (ARMMs) as a delivery platform for nucleic acid and protein therapeutics. Shares Ciloa's focus on engineering sEVs as a modular delivery vehicle rather than unmodified natural vesicles.

TypeDirect peer
Description

Korean biotech developing exosome-based therapeutics using engineered extracellular vesicles to deliver therapeutic proteins intracellularly. Closely comparable to Ciloa's protein-loading sEV approach and platform-based development model.

TypeDirect peer
Description

Clinical-stage biotech developing extracellular vesicle therapies derived from mesenchymal stem cells for inflammatory and dermatologic indications. Comparable to Ciloa as a focused EV-therapeutics developer with clinical-stage assets.

6Aruna Bio
TypeDirect peer
Description

US biotech developing neural-derived exosomes (AB-126) for CNS and inflammatory indications. Comparable to Ciloa as a specialty extracellular vesicle therapeutics company targeting indications beyond a single disease area.

TypeBroad incumbent
Description

Global leader in diabetes and obesity care with the dominant GLP-1 franchise (Ozempic, Wegovy). Sets the standard-of-care benchmark that any new metabolic disease entrant like APN-sEV must beat or differentiate against on efficacy, safety, and muscle preservation.

TypeBroad incumbent
Description

Major incumbent in obesity and T2D with Mounjaro/Zepbound (tirzepatide) and an active metabolic pipeline. Comparable to Ciloa as the second dominant force defining the obesity therapeutic landscape and the primary competitive reference for APN-sEV.

TypeEmerging player
Description

Clinical-stage biotech developing peptide therapeutics for metabolic disease, including obesity and diabetes. Comparable to Ciloa as a smaller-cap metabolic disease specialist pursuing differentiated mechanisms against the GLP-1 incumbents.

TypeEmerging player
Description

Clinical-stage biotech developing therapeutics for metabolic diseases of aging, including obesity. Comparable to Ciloa as a development-stage company targeting metabolic indications with differentiated mechanisms and similar pre-commercial timelines.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ciloa

Biopharmaceutical Therapeuticsciloa.fr

Ciloa is a French pre-revenue biotech developing bioengineered small extracellular vesicles (sEVs) via its proprietary EVENGI platform, with a lead APN-sEV candidate targeting obesity and type 2 diabetes through planned Phase I trials in 2027.

What Ciloa does

Ciloa SAS is a French privately-held biotechnology company founded in 2011 and headquartered in Montpellier, France, specializing in the bioengineering of small extracellular vesicles (sEVs/exosomes) for therapeutic and preventive applications. The company's core technology is the proprietary EVENGI platform, developed over 20 years of extracellular vesicle research, which has generated over 100 different bioengineered sEVs containing proteins of medical interest. Its lead product candidate is APN-sEV — sEVs loaded with stable, highly multimerised, functional adiponectin hormone — targeted at metabolic diseases including obesity, type 2 diabetes, MAFLD/MASH, and cardiovascular disease, with clinical trials (Phase I in 2027, Phase IIa in 2028) planned for the APN-sEV candidate.

Ciloa's business model is a pre-revenue biopharmaceutical development model: the company is not yet commercializing any products and will generate revenue through future drug commercialization or licensing once its therapeutic candidates complete clinical trials and receive regulatory approval. The platform also supports applications in oncology, rare diseases, age-related illnesses, and viral pandemic preparedness through sEV-based vaccines. To date, the company has been funded primarily through non-dilutive government grants, securing €5 million in March 2022 from the France 2030 initiative for biomedicines and vaccines development, and €6.5 million in July 2025 under the 'DIADEME' project for scaling up manufacturing and advancing APN-sEV through preclinical and clinical trials, bringing cumulative disclosed funding to approximately €11.5 million.

The company operates with a small team (1-10 employees) and pursues an enterprise-oriented go-to-market, engaging potential pharmaceutical partners and investors through industry conferences such as BIO US 2025 (as part of the French Delegation) and the EU-Japan Biotech & Pharma Conference. Ciloa has also entered a strategic co-development partnership with Bio-Sourcing and Intract Pharma under the AB-BIOBETTER EU project (€3.4 million total, €1.9 million in Eureka Eurostars subsidies) to develop an oral formulation of adalimumab for inflammatory indications, demonstrating a willingness to expand the platform beyond metabolic disease applications.

Ciloa firmographics

Firmographics
Name
Ciloa
Legal name
Ciloa SAS
Website
https://ciloa.fr
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Short description
Ciloa is a French pre-revenue biotech developing bioengineered small extracellular vesicles (sEVs) via its proprietary EVENGI platform, with a lead APN-sEV candidate targeting obesity and type 2 diabetes through planned Phase I trials in 2027.
Ownership category
akta.pro rank

Ciloa industry classification

Industry
Product category
Biopharmaceutical Therapeutics
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Dog and Cat Food Manufacturing (311111)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Extracellular vesicles therapeutics
  • Biopharmaceutical drug development
  • Metabolic disease treatments
  • Exosome bioengineering
  • Adiponectin therapeutics

Where Ciloa is headquartered

Location

Headquarters

HQ city
Montpellier
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Ciloa business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Therapeutic Drug Development: Pre-revenue biopharmaceutical company developing drug candidates (APN-sEV) for obesity and type 2 diabetes. Revenue will be generated through eventual drug commercialization pending successful clinical trials and regulatory approvals.

Go-to-market motion1 record

Marketing channels3 records

Ciloa product offering

Product offering

Core offering

Ciloa develops bioengineered small extracellular vesicles (sEVs/exosomes) as therapeutic drug candidates using its proprietary EVENGI platform. Its lead candidate, APN-sEV, consists of sEVs loaded with stable, highly multimerised functional adiponectin hormone and targets metabolic diseases—specifically obesity, type 2 diabetes, MAFLD/MASH, and cardiovascular disease—by restoring insulin sensitivity, reducing lipogenesis, and preserving lean muscle mass. The pipeline also extends to oncology, rare diseases, age-related illnesses, and vaccine development against viral pandemics.

Product overview

Ciloa is a biotech company pioneering the bioengineering of small extracellular vesicles (sEVs/exosomes) as natural therapeutic messengers. The company's core offering centers on its proprietary EVENGI Platform, which generates bioengineered sEVs containing proteins of medical interest. The lead product is APN-sEVs—sEVs containing functional adiponectin hormone—for treating metabolic diseases including obesity, type 2 diabetes, MAFLD/MASH, and cardiovascular diseases. Ciloa's technology enables stable, ready-to-use, affordable medicines that can be stored in refrigerators for years.

Differentiator

Problem solved

Functional benefit

Products and services

  • APN-sEVs Bioengineered small extracellular vesicles (sEVs) containing stable, highly multimerised and functional adiponectin hormone, developed as therapeutic drug candidates for metabolic diseases including obesity and type 2 diabetes. APN-sEVs provide insulin-sensitizing, anti-inflammatory, and anti-oxidative stress properties while protecting lean muscle mass during treatment.

Quantifiable outcome

  • Spectacular effects on obesity and diabetes characterized by decreased circulating adiponectin

Companies that use Ciloa

Customer profile

Segments3 records

Ideal customer profiles2 records

Ciloa technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Ciloa partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Bio-SourcingcoreStrategic or Co-development Partner · 28 May 2024Ciloa partnered with Bio-Sourcing and Intract Pharma on the AB-BIOBETTER project, a €3.4 million EU project funded with €1.9M subsidies from Eureka Eurostars. The project aims to pioneer development of new oral formulation of adalimumab for inflammatory indications.
  • Intract PharmacoreStrategic or Co-development Partner · 28 May 2024Ciloa partnered with Bio-Sourcing and Intract Pharma on the AB-BIOBETTER project, a €3.4 million EU project funded with €1.9M subsidies from Eureka Eurostars. The project aims to pioneer development of new oral formulation of adalimumab for inflammatory indications.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Ciloa competitors and assessment

Company assessment

Direct peers

  • Evox Therapeutics: UK-based biotech engineering exosomes/extracellular vesicles for therapeutic delivery of proteins, RNA, and other payloads across rare diseases and CNS indications. Most directly comparable to Ciloa's EVENGI platform given shared core modality of bioengineered sEVs for therapeutic use.
  • Capricor Therapeutics: Clinical-stage biotech developing extracellular vesicle-based therapeutics, including lead program CAP-1002 for Duchenne muscular dystrophy and inflammatory conditions. Comparable to Ciloa as an EV-therapeutics pure-play advancing assets toward clinical milestones.
  • Vesigen Therapeutics: US biotech developing engineered extracellular vesicles (ARMMs) as a delivery platform for nucleic acid and protein therapeutics. Shares Ciloa's focus on engineering sEVs as a modular delivery vehicle rather than unmodified natural vesicles.
  • ILIAS Biologics: Korean biotech developing exosome-based therapeutics using engineered extracellular vesicles to deliver therapeutic proteins intracellularly. Closely comparable to Ciloa's protein-loading sEV approach and platform-based development model.
  • Aegle Therapeutics: Clinical-stage biotech developing extracellular vesicle therapies derived from mesenchymal stem cells for inflammatory and dermatologic indications. Comparable to Ciloa as a focused EV-therapeutics developer with clinical-stage assets.
  • Aruna Bio: US biotech developing neural-derived exosomes (AB-126) for CNS and inflammatory indications. Comparable to Ciloa as a specialty extracellular vesicle therapeutics company targeting indications beyond a single disease area.

Broad incumbents

  • Novo Nordisk: Global leader in diabetes and obesity care with the dominant GLP-1 franchise (Ozempic, Wegovy). Sets the standard-of-care benchmark that any new metabolic disease entrant like APN-sEV must beat or differentiate against on efficacy, safety, and muscle preservation.
  • Eli Lilly: Major incumbent in obesity and T2D with Mounjaro/Zepbound (tirzepatide) and an active metabolic pipeline. Comparable to Ciloa as the second dominant force defining the obesity therapeutic landscape and the primary competitive reference for APN-sEV.

Emerging players

  • Zealand Pharma: Clinical-stage biotech developing peptide therapeutics for metabolic disease, including obesity and diabetes. Comparable to Ciloa as a smaller-cap metabolic disease specialist pursuing differentiated mechanisms against the GLP-1 incumbents.
  • BioAge Labs: Clinical-stage biotech developing therapeutics for metabolic diseases of aging, including obesity. Comparable to Ciloa as a development-stage company targeting metabolic indications with differentiated mechanisms and similar pre-commercial timelines.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

Ciloa social profiles

Digital presence

Ciloa financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ciloa leadership team

Management profile

Number of profiles

Profiles2 records

Ciloa funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ciloa M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ciloa

What does Ciloa do?

Ciloa develops bioengineered small extracellular vesicles (sEVs/exosomes) as therapeutic drug candidates using its proprietary EVENGI platform. Its lead candidate, APN-sEV, consists of sEVs loaded with stable, highly multimerised functional adiponectin hormone and targets metabolic diseases—specifically obesity, type 2 diabetes, MAFLD/MASH, and cardiovascular disease—by restoring insulin sensitivity, reducing lipogenesis, and preserving lean muscle mass. The pipeline also extends to oncology, rare diseases, age-related illnesses, and vaccine development against viral pandemics.

Is Ciloa a public or private company?

Ciloa is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Ciloa founded?

Ciloa was founded in 2011. It employs 11 to 50 people.

Where is Ciloa based?

Ciloa is headquartered in Montpellier, France, in the Europe region.

How does Ciloa make money?

One revenue line is on record: therapeutic Drug Development.

Who are Ciloa's main competitors?

Direct peers on record are Evox Therapeutics, Capricor Therapeutics, Vesigen Therapeutics, ILIAS Biologics, Aegle Therapeutics and Aruna Bio. Broad incumbents are Novo Nordisk and Eli Lilly. Emerging players are Zealand Pharma and BioAge Labs.

Does Ciloa have an API?

No public API is recorded for Ciloa.

What industry is Ciloa in?

Ciloa's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization), with a secondary code of HLAAAAAJ, Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds). Its NAICS code is 334510 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
European BiotechnologyInside exosomes: Nature’s drug carriersExosomes are being developed as drug carriers to overcome delivery hurdles, with companies like Evox Therapeutics and Aruna Bio advancing CNS and stroke therapies. Evox targets Huntington's disease with a Phase 1/2 trial planned for 2027, while Aruna Bio's AB126 reached Phase 1b. The field is expected to see IP consolidation and manufacturability breakthroughs over the next 5–10 years.PharmiWeb.comCiloaCiloa, a French biotech company specializing in in-vivo bio-engineering of small extracellular vesicles for therapeutic and preventive applications, has secured €6.5 million in funding. The company stated it wished to raise its profile and earn broader market recognition, particularly for its applications in metabolic-disease treatment. The funding announcement was made on October 2, 2025.The Pharma LetterCiloa steps into crowded metabolic drug space with exosome-based approachFrench biotech Ciloa is entering the metabolic drug space with a new exosome-based approach to treat type 2 diabetes and obesity, supported by 6.5 million euros in public funding.EU-StartupsFrench scale-up Ciloa raises €6.5 million to advance exosome therapy for metabolic diseasesFrench biotechnology company Ciloa secured €6.5 million in funding from the France 2030 initiative to advance its APN-sEV therapy for metabolic diseases. The capital will support clinical development up to phase IIa trials for type 2 diabetes and obesity, as well as large-scale GMP manufacturing implementation. Clinical trials are scheduled to begin in 2027, followed by phase IIa in 2028.CiloaCiloa secures €6.5 million government funding from France 2030 ‘Innovation in biotherapies and biomanufacturing’ to develop drug candidate for treatment of obesity and type 2 diabetes – ciloa.bioCiloa secured €6.5 million from France 2030 to develop its APN-sEV drug candidate for obesity and type 2 diabetes. The funding will support GMP manufacturing and preclinical trials, with phase I planned for 2027 and phase IIa for 2028.PharmiWeb.comCiloa secures €6.5 million government funding from France 2030 ‘Innovation in biotherapies and biomanufacturing’ to develop drug candidate for treatment of obesity and type 2 diabetesCiloa secured €6.5 million from France 2030 to develop its APN-sEV drug candidate for obesity and type 2 diabetes. The funding will support GMP manufacturing and preclinical trials, with phase I planned for 2027 and phase IIa for 2028.PharmiWeb.comBio-Sourcing, Ciloa and Intract Pharma launch €3.4M EU project in inflammatory indications with €1.9M subsidies from EUREKA EurostarsBio-Sourcing, Ciloa, and Intract Pharma launched a €3.4M EU project to develop an oral adalimumab formulation for inflammatory bowel diseases, with €1.9M in EUREKA Eurostars subsidies. The three-year program aims to preclinically validate the product and reach IND-enabling studies.